Adagio Medical Holdings, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ADGM$1.84-4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · · Accumulated · · | |||||||||||||||||||||||
| · · Convertible · · · · · · · · Additional · · · · · Other · · Total | |||||||||||||||||||||||
| · · Preferred Stock · · · Common Stock · · Paid-in · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||||||||
| · Shares · Amount · Shares · Amount · Capital · Deficit · Income · Equity (Deficit) | |||||||||||||||||||||||
| Balance as of December 31, 2022 (Predecessor) | 4,939,946 | | $91,469 | | 756,160 | | $1 | | $1,153 | | $(97,059) | | $28 | | $(95,877) | ||||||||
| Foreign currency translation adjustment | — | | — | | — | | — | | — | | — | | (11) | | (11) | ||||||||
| Stock option exercises | — | | — | | 23,748 | | — | | 13 | | — | | — | | 13 | ||||||||
| Stock-based compensation | — | | — | | — | | — | | 442 | | — | | — | | 442 | ||||||||
| Net loss | — | | — | | — | | — | | — | | (36,590) | | — | | (36,590) | ||||||||
| Balance, December 31, 2023 (Predecessor) | 4,939,946 | | $91,469 | | 779,908 | | $1 | | $1,608 | | $(133,649) | | $17 | | $(132,023) | ||||||||
| Foreign currency translation adjustment | — | | — | | — | | — | | — | | — | | 3 | | 3 | ||||||||
| Exchange preferred stock for pre-funded warrants | | (207,902) | | | (4,686) | | | — | | | — | | | 4,332 | | | — | | | — | | | 4,332 |
| Stock option exercises | — | | — | | 305 | | — | | 9 | | — | | . | | 9 | ||||||||
| Stock-based compensation | — | | — | | — | | — | | 642 | | — | | — | | 642 | ||||||||
| Net loss | — | | — | | — | | — | | — | | (21,278) | | — | | (21,278) | ||||||||
| Balance as of July 30, 2024 (Predecessor) | 4,732,044 | | $86,783 | | 780,213 | | $1 | | $6,591 | | $(154,927) | | $20 | | $(148,315) | ||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Balance as of July 31, 2024 (Successor) | | — | | $— | | | 13,387,636 | | $1 | | $89,786 | | $(16,823) | | $— | | $72,964 | ||||||
| Foreign currency translation adjustment | — | | — | | — | | — | | — | | — | | 1 | | 1 | ||||||||
| Exercise of pre-funded warrants | | — | | — | | 663,096 | | 1 | | 709 | | — | | — | | 710 | |||||||
| Issuance of earn-out shares | | — | | — | | 1,147,500 | | — | | — | | — | | — | | — | |||||||
| Net loss | — | | — | | — | | — | | — | | (53,763) | | — | | (53,763) | ||||||||
| Balance, December 31, 2024 (Successor) | — | | $— | | 15,198,232 | | $2 | | $90,495 | | $(70,586) | | $1 | | $19,912 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.